A Cardio-Oncological Mice Model of Anthracycline-Induced Cardiotoxicity in Breast Tumor-Bearing Immunocompetent Mice
Journal of Visualized Experiments · 2026
DOI: 10.3791/71633 ↗At a glance
Video/Audio in Journal of Visualized Experiments, 2026. Written by Hugo Nordin and 5 co-authors. Institution: INSERM UMR-S 942 MASCOT, Cardiovascular Biomarkers, Pathophysiology, and Therapeutic Strategies - CIRCUS, Paris Cité University. Major MEDLINE topics: Disease Models, Animal, Antibiotics, Antineoplastic, Anthracyclines, Doxorubicin.
Abstract (original language)
The recent update from the European Society of Cardiology on preclinical models of cancer therapy-related cardiac dysfunction highlights a critical need for more representative and translational in vivo models. It pinpoints the need to develop models that employ immunocompetent, tumor-bearing animals, incorporating multiple strains and both sexes, to more accurately recapitulate the heterogeneity observed in clinical populations. Therefore, a clinically relevant model of anthracycline-induced cardiotoxicity (AIC) in breast tumor-bearing animals was built. According to mice' genetic background, either 4T1Luc-cells (200k cells) or PY8119-cells (200k cells) were injected in Balb/c-mice or C57Bl/6J-mice, respectively subcutaneously in the lower mammary gland of males and females. Tumor growth was controlled with bioluminescence and palpation. Once the tumor mass was detectable by palpation, 2 weeks post-tumor cell injection, animals received anticancer Doxorubicin treatment. Mice's tolerance to Doxorubicin was strain-dependent. Cardiac function was evaluated before the start of the protocol (baseline) and weekly after by cardiac ultrasound in ketamine-anesthetized mice. Cardiotoxicity was defined as a decrease in left ventricular fractional shortening of at least 10% from baseline, an absolute value 300 BPM. The protocol was reproducible with a 99% success of tumor development, and a >80% mice survival rate. Cardiotoxicity was observed in >90% of the treated mice with tumor and Doxorubicin.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- INSERM UMR-S 942 MASCOT, Cardiovascular Biomarkers, Pathophysiology, and Therapeutic Strategies - CIRCUS, Paris Cité University.
- Medical and Surgical Intensive Care Unit, University Hospital Avicenne, AP-HP.
- INSERM UMR-S 942 MASCOT, Cardiovascular Biomarkers, Pathophysiology, and Therapeutic Strategies - CIRCUS, Paris Cité University; feriel.azibani@inserm.fr.
Cite
APA
Nordin, H., Assad, N., Nguyen, A., Gonçalves, T., Picod, A., & Azibani, F. (2026). A Cardio-Oncological Mice Model of Anthracycline-Induced Cardiotoxicity in Breast Tumor-Bearing Immunocompetent Mice. Journal of Visualized Experiments. https://doi.org/10.3791/71633
Vancouver
Nordin H, Assad N, Nguyen A, Gonçalves T, Picod A, Azibani F. A Cardio-Oncological Mice Model of Anthracycline-Induced Cardiotoxicity in Breast Tumor-Bearing Immunocompetent Mice. Journal of Visualized Experiments. 2026. doi:10.3791/71633
BibTeX
@article{Nordin2026,
author = {Nordin, Hugo and Assad, Noma and Nguyen, Alexis and Gonçalves, Trecy and Picod, Adrien and Azibani, Feriel},
title = {A Cardio-Oncological Mice Model of Anthracycline-Induced Cardiotoxicity in Breast Tumor-Bearing Immunocompetent Mice},
journal = {Journal of Visualized Experiments},
year = {2026},
doi = {10.3791/71633}
}
EUVIMED